India's DMPLOI - Jobs & Networking App
Aurobindo Pharma is inviting passionate and skilled professionals to join its Regulatory Affairs team. The openings are for candidates with hands-on experience in Regulatory Affairs (Formulation – OSD) for US, Europe, and Canada markets.
Available Positions
For the US Market:
Candidates should have experience in CMC-M2-M3, post-approval activities, annual report submissions, and query handling.
Experience: 6 to 10 years
Qualification: M. Pharmacy in Regulatory Affairs, Pharmaceutics, or Pharmaceutical Analysis
For the Europe Market:
The role involves working on administrative modules and handling submissions for DCP, RUP, and NP procedures.
Experience: 4 to 6 years
Qualification: M. Pharmacy in Regulatory Affairs or Pharmaceutics
For the Canada Market:
Responsibilities include managing M2 & M3 for the CA market, working on the quality module, and reviewing plant-related documents.
Experience: 3 to 5 years
Qualification: M. Pharmacy in Regulatory Affairs, Pharmaceutics, or Quality Assurance
Location:
Bachupally, Hyderabad
How to Apply:
Interested candidates can send their resumes to Sreeja.Yangam@aurobindo.com
Sreeja. Yangam@aurobindo.com
with the subject line:
👉 “Application – Regulatory Affairs”
Top Regulatory Affairs Interview Questions & Answers
General Regulatory Affairs (Formulation – OSD)
Q1. What is the role of Regulatory Affairs in a pharmaceutical company?
A: Regulatory Affairs ensures that all pharmaceutical products comply with global regulatory standards. The department manages submissions (like ANDA, NDA, or MAA), handles post-approval changes, annual reports, and maintains communication with regulatory authorities to ensure product compliance through its lifecycle.
Q2. What are Modules 1 to 5 in the CTD format?
A:
Module 1: Administrative & Product Information (region-specific)
Module 2: CTD Summaries
Module 3: Quality (CMC)
Module 4: Nonclinical Study Reports
Module 5: Clinical Study Reports
US Market (FDA) Related
Q3. What are CMC sections M2 and M3?
A:
M2 (Quality Overall Summary): Summarizes key quality information.
M3 (Quality Module): Contains detailed data about drug substance and product — manufacturing process, control of materials, stability data, and specifications.
Q4. What are Post-Approval Changes?
A: These are updates made to an approved application, such as changes in manufacturing site, formulation, batch size, or packaging. They are categorized by the FDA as:
CBE-0 (Changes Being Effected immediately),
CBE-30 (notify 30 days before implementation),
PAS (Prior Approval Supplement).
Q5. What are Annual Reports?
A: Annual reports are mandatory submissions to the FDA summarizing all manufacturing and quality changes made during the year for an approved ANDA/NDA product.
Q6. What is Query Handling in RA?
A: Query handling involves responding to questions from regulatory authorities (like FDA or EMA) during submission review. It requires cross-functional coordination to provide scientific and technical justifications within defined timelines.
Europe Market (EMA)
Q7. What are DCP, RUP, and NP procedures?
A:
DCP (Decentralized Procedure): Used for marketing authorization in multiple EU countries simultaneously.
RUP (Repeat Use Procedure): Used to extend existing DCP authorizations to additional EU countries.
NP (National Procedure): Used when approval is sought in one EU country only.
Q8. What documents are required for an MAA (Marketing Authorization Application)?
A: Administrative information, CTD Modules 1–5, product information (SmPC, PIL, labeling), and GMP certificates.
Q9. What is the role of the Administrative Module in EU submissions?
A: The Administrative Module (Module 1) includes application forms, product information, labeling, and proof of payment, and is specific to each EU member state.
Canada Market (Health Canada)
Q10. What are M2 & M3 requirements for Canada submissions?
A: Similar to CTD format, M2 and M3 include summaries and quality data as per Health Canada’s Guidance for Industry. However, Canada-specific elements such as eCTD envelope metadata and cross-references to Drug Master Files (DMFs) are required.
Q11. What is a Quality Module?
A: It details the product’s chemistry, manufacturing, and controls (CMC) — covering raw materials, analytical methods, specifications, and validation reports.
Q12. What are common Health Canada deficiencies in OSD submissions?
A:
Incomplete stability data
Lack of justification for analytical methods
Missing site GMP evidence
Inconsistent specifications between sections
Behavioral / Soft Skill Questions
Q13. How do you manage tight submission timelines?
A: By maintaining a detailed submission tracker, prioritizing based on regulatory deadlines, ensuring proactive communication with cross-functional teams, and preparing documentation in advance.
Q14. Describe a challenging regulatory query you handled.
A: Provide a STAR response (Situation, Task, Action, Result). For example: “During a USFDA review, a query was raised on dissolution profile variation. I collaborated with the formulation and QA teams, provided data justification with comparative profiles, and the query was closed successfully.”
Q15. What do you enjoy most about working in Regulatory Affairs?
A: The dynamic nature of the role — combining science, strategy, and compliance — and its direct impact on bringing safe and effective medicines to patients globally.
